bluuebunny/crossref_metadata_2025_split huggingface dataset:
(300) SEXUAL HEALTH PRACTITIONER PATTERNS FOR THE ASSESSMENT OF PATIENTS’ ORGASM CONCERNS
Authors: Burr E , Messafi A , Agrawal J , Perlmuter S , Forer R , Tran Q , Poirier E , Rubin R 
Published: December 2024

Abstract

Introduction
Medical knowledge of orgasm dysfunction has shifted in recent years to include a wide range of conditions that impact multiple domains of orgasm. It is currently unknown how sexual medicine practitioners are adjusting their practice patterns to ensure comprehensive assessment of patients’ orgasm concerns.

Objective
This study aims to elucidate the current state of orgasm assessment by surveying sexual medicine practitioners. This study’s primary outcome was to identify the method of orgasm assessment utilized by sexual medicine practitioners, exploring both the use of patient reported outcome measures (PROMs) and patient interviews. A secondary outcome was to explore practitioner reasons for utilizing their assessment tool as well as satisfaction with their current practice pattern.

Methods
Data were collected via an anonymous 33-question survey distributed from January 7, 2024, to April 14, 2024. The survey asked participants about their practice patterns for assessing orgasm via multiple choice and free response. Qualtrics software was used to create, distribute, and analyze the survey and NVivo14 was used to perform qualitative analysis.

Results
Of the 87 survey responses analyzed, 86 (99%) practitioners felt that it is important to assess orgasm as part of sexual health. Most respondents utilized interviews, with 56% of respondents using patient interviews alone and 34% combining interviews with validated PROMs. Regardless of the assessment modality, approximately 25% of the respondents expressed dissatisfaction with the current modalities for assessing orgasm function. Qualitative responses emphasized the benefits of interviews, including their ability to support detailed and individualized care. Additional barriers to using PROMs included practice limitations such as lack of time and practitioner lack of knowledge about and confidence in orgasm-specific PROMs.

Conclusions
This study’s findings suggest a significant reliance on interviews over standardized PROMs for assessing orgasm, likely due to the complex, multifactorial nature of orgasm dysfunction as well as lack of knowledge about or confidence in existing orgasm-specific PROMs. Respondents’ dissatisfaction with existing assessment modalities indicates a potential gap in adequate tools to address orgasm dysfunction. Future research should focus on developing more comprehensive, patient-centered assessment strategies that retain qualities of interviews and PROMs.

Disclosure
No.
(317) EVALUATING PRACTICE PATTERNS OF CLOSTRIDIUM COLLAGENASE HISTOLYTICUM PROVIDERS
Authors: Vasdev R , Parikh N , Sischka M , Ziegelmann M 
Published: December 2024

Abstract

Introduction
Clostridium Collagenase Histolyticum (CCH) is the only-FDA approved non-surgical, intralesional option for men with Peyronie’s disease. However, little is known regarding practice patterns of CCH providers due to lack of standardized protocols.

Objective
To evaluate practice patterns for providers approved to administer CCH to treat Peyronie’s disease (PD), this study was conducted.

Methods
The “Find a Xiaflex-Trained Urologist” search tool on the Endo International patient-facing website was utilized to identify clinicians offering CCH injections in the United States. A 24-question survey was mailed to these providers with topics including provider type, years in practice, therapies offered, and patient evaluation was distributed to providers on patient-facing Endo International Xiaflex Find a Provider web-based tool.

Results
63 responses were obtained, including 41% fellowship-trained urologists (FTU), 40% non-fellowship-trained urologists (NFTU), 14% advanced practice providers, and 5% un-specified. Prior to therapy, over 63% of providers performed in-office assessment of an erect penis while only 35% obtained ultrasound. 32% always and 36% never performed an artificial erection prior to administering CCH. Plaques were most identified by palpation or patient-provided direction with penile modeling and traction the most common adjuncts. When comparing NFTU to FTU, there was no difference in volume of PD patients with 60% examining fewer than 10 per month. FTU were more likely to offer traction (p = 0.002), plaque incision/excision and grafting (p = 0.005), increase time between injections (p = 0.012), and less likely to encourage penetrative intercourse between cycles (p = 0.016). The incidence of post-operative hematomas or suspected corporal rupture was not significantly different, although FTUs were more likely to conservatively manage rupture.

Conclusions
Variability exists in provider practice patterns surrounding CCH injections with most evaluating less than 10 patients with PD per month. This calls to attention the need for evaluation of techniques, patient outcomes, and standardization of care.

Disclosure
Yes, this is sponsored by industry/sponsor: Endo Pharmaceuticals.
Clarification: Industry funding only - investigator initiated and executed study.
Any of the authors act as a consultant, employee or shareholder of an industry for: Endo Pharmaceuticals.
(322) PATIENT OUT-OF-POCKET COSTS FOR GUIDELINE-RECOMMENDED TREATMENTS FOR ERECTILE DYSFUNCTION: A MEDICARE COST MODELING ANALYSIS
Authors: Nguyen V , Mcgovern A , Rojanasarot S , Patel D , Bhattacharyya S , Hargens L , Aworunse O , Hsieh T 
Published: December 2024

Abstract

Introduction
Patient out-of-pocket (OOP) cost represents a barrier to accessing treatment for erectile dysfunction (ED). Many physicians have limited insight into the costs and insurance coverage of the treatment options that they recommend.

Objective
We sought to evaluate OOP costs incurred by men with ED covered by Fee-for-Service Medicare.

Methods
The 2018 American Urological Association (AUA) guidelines were used to identify recommended ED treatments. Coverage policies were obtained from the Medicare Coverage Database. OOP costs were retrieved from the 2023 CMS Final Rule. For treatments not covered by Medicare, OOP costs were extracted from GoodRx® or published literature and inflated to 2022 dollars. Annual prescription costs were calculated using a published estimate of 52.2 instances of sexual intercourse per year. The estimated number of Medicare patients with ED (n = 254,650) was used to evaluate healthcare system implications.

Results
Medicare has established coverage for inflatable penile prostheses (IPP; strong recommendation), non-coverage for vacuum erection devices (VED; moderate recommendation) and phosphodiesterase type-5 inhibitors (PDE5i; strong recommendation), and no existing policies for intracavernosal injections (ICI; moderate recommendation), intraurethral alprostadil (IA; conditional recommendation), or extracorporeal shock wave therapy (ESWT; conditional/investigational recommendation; Table 1). Annual IA prescription is associated with the highest patient OOP cost ($4,022), followed by annual ICI prescription ($3,947), one ESWT treatment course ($3,445), IPP ($1,600; inpatient deductible), annual PDE5i prescription ($696), and one VED ($213; Fig. 1). Among PDE5i, avanafil is associated with the highest annual OOP cost ($3,455), followed by vardenafil ($2,102), tadalafil ($723), and sildenafil ($459). One-year projections demonstrate IA is associated with the highest national healthcare OOP cost ($1.02 billion), followed by ICI ($1.0 billion), ESWT ($877 million), IPP ($407 million), PDE5i ($177 million), and VED ($54 million).

Conclusions
PDE5i and IPP are cost-effective options with strong guideline recommendations. Better understanding of patient financial burden may improve shared decision making with patients who suffer from ED.

Disclosure
Yes, this is sponsored by industry/sponsor: Boston Scientific.
Clarification: Industry funding only - investigator initiated and executed study.
Any of the authors act as a consultant, employee or shareholder of an industry for: Boston Scientific.
(324) EX-VIVO DEMONSTRATION OF A NOVEL METHOD FOR AUTO-INFLATION PREVENTION IN PATIENTS WITH INFLATABLE PENILE PROSTHESIS
Authors: Howell S , Mahdi M , Albakr A , Wang R 
Published: December 2024

Abstract

Introduction
Inflatable penile prosthesis (IPP) is a surgical treatment for refractory erectile dysfunction which has repeatedly demonstrated a high patient and partner satisfaction rate. Three-piece IPPs are associated with the highest satisfaction of different implants due to alternating excellent rigidity and flaccidity. Despite the high satisfaction rate enabled by the reservoir, mechanical dysfunction associated with this piece may conversely lead to poor satisfaction and re-intervention. One reported mechanical dysfunction is auto-inflation, in which there is propagation of fluid from the reservoir to the cylinders without manual action on the pump. Auto-inflation leads to annoyance and discomfort at best. At worst, significant morbidity has been reported including device erosion into the urethra. To overcome auto-inflation, Coloplast devices contain a lockout valve in the reservoir itself, while Boston Scientific devices have the lockout valve in the pump. Nevertheless, auto-inflation remains a source of dissatisfaction, with management potentially requiring revisional surgery in patients with significant bother.

Objective
We describe a simple technique for prevention of auto-inflation of inflatable penile prostheses (IPP) by using 1-2 pump squeezes and demonstrate this ex-vivo.

Methods
The pump/cylinder units of both Coloplast Titan and Boston Scientific AMS 700 devices were tested separately within the operating room. Auto-inflation Simulation: A 60 cc Luer lock syringe is used to inject normal saline solution into the pump/cylinders while the device is in deflation mode. A reasonable pressure is applied during injection. Cylinder inflation is observed only in the Titan device, suggesting potential auto-inflation. Prevention Maneuver: The Titan cylinders are manually deflated. Following this, the pump is squeezed once or twice. The Luer lock syringe is then used to attempt to inject normal saline, but in this case is unsuccessful using reasonable pressure application. Confirmatory Maneuver: The above procedure is repeated for the AMS 700 device. Normal saline is still unable to be propagated into the cylinder after 1-2 squeezes of the pump.

Results
Our findings demonstrate that the simple maneuver of one to two pump squeezes after deflation effectively prevents auto-inflation in the Coloplast Titan IPP. The efficacy of this technique has been further validated in a clinical setting. Five patients experiencing auto-inflation with the Titan device were treated using this maneuver, and it successfully resolved the issue in all cases.

Conclusions
The simple technique of one to two pump squeezes after IPP device deflation demonstrates a non-invasive method for prevention of IPP auto-inflation.

Disclosure
No.
Primaquine treatment for P. ovale infection in migrants with G6PD deficiency
Authors: Rubio Maturana Carles , Martínez-Vallejo Patricia , Salvador Fernando , Beneitez-Pastor David , Serrat Francesc Zarzuela , Sulleiro Elena , Pou Diana , Aznar Maria Luisa , Molina Israel , Serre-Delcor Núria , Oliveira-Souto Inés 
Published: December 2024

Four patients from Sub-Saharan Africa were infected by Plasmodium ovale and simultaneously presented with glucose-6-phosphate dehydrogenase deficiency. Primaquine 0.75 mg/kg once a week during 8 weeks was administered with a close hematologic follow-up. Non-significant alterations in hemogram and hemolytic parameters were observed in any case.
Chinese Whispers: Contextualizing the Finale of Messiaen’s Et exspecto
Authors: Cheong Wai-Ling , Tse Chun-Yan 
Published: December 2024

ABSTRACT
The incessant, evenly spaced tolling of gongs throughout the 6-minute-long finale of Olivier Messiaen’s Et exspecto resurrectionem mortuorum presents a unique sonic phenomenon within the Western orchestral tradition. It nonetheless resonates with distinct features of the ‘Hymne du temple des Ancêtres’ and the ‘Hymne à Confucius’ Messiaen cited under the section ‘Les modes Chinois’ in Traité de rythme, de couleur, et d’ornithologie, volume vii. Through a comparative analysis of Western and Chinese sources related to the two hymns, we garner evidence to argue for cross-cultural intertextuality in Messiaen’s finale, and to speculate on the sources he might have (mis)read when commenting intriguingly on the Chinese modes and religious music prior to citing the specific hymns. Not least because the two hymns are emblematic of the Ming and the Qing dynasty, the story of their transmission to the West—arguably politically motivated—also throws light on the power dynamics between the rival dynasties.
The formation of supermassive black holes from Population III.1 seeds. III. Galaxy evolution and black hole growth from semi-analytic modelling
Authors: Cammelli Vieri , Monaco Pierluigi , Tan Jonathan C , Singh Jasbir , Fontanot Fabio , De Lucia Gabriella , Hirschmann Michaela , Xie Lizhi 
Published: December 2024

ABSTRACT
We present an implementation of Pop III.1 seeding of supermassive black holes (SMBHs) in a theoretical model of galaxy formation and evolution to assess the growth of the SMBH population and the properties of the host galaxies. The model of Pop III.1 seeding involves SMBH formation at redshifts $z\gtrsim 20$ in dark matter minihaloes that are isolated from external radiative feedback, parametrized by isolation distance $d_{\rm iso}$. Within a standard $\Lambda$CDM cosmology, we generate dark matter haloes using the code pinocchio and seed them according to the Pop III.1 scenario, exploring values of $d_{\rm iso}$ from 50 to 100 kpc (proper distance). We consider two alternative cases of SMBH seeding: a halo mass threshold model in which all haloes $\gt 7\times 10^{10}\,\rm M_\odot$ are seeded with $\sim 10^5\,\rm M_\odot$ black holes; an all light seed model in which all haloes are seeded with low, stellar mass black holes. We follow the redshift evolution of the haloes, populating them with galaxies using the GAlaxy Evolution and Assembly theoretical model of galaxy formation, including accretion on SMBHs and related feedback processes. Here we present predictions for the properties of galaxy populations, focusing on stellar masses, star formation rates, and black hole masses. The local, $z\sim 0$ metrics of occupation fraction as a function of the galaxy stellar mass, galaxy stellar mass function, and black hole mass function all suggest a constraint of $d_{\rm iso}\lt 75\:$ kpc. We discuss the implications of this result for the Pop III.1 seeding mechanism.
Rotation signal on the full disc of the solar chromosphere
Authors: Wan M , Deng L H , Zeng S G , Yan Z J , Xie J L , Xu T T , Yu Y T 
Published: December 2024

ABSTRACT
The rotation signal on the full disc of the solar chromosphere was studied by using the Ca ii K normalized intensity from 938 Carrington rotation (CR) synoptic maps (from CR827 to CR1764) obtained from the Mount Wilson Observatory during the period of 1915 August 10 to 1985 July 7. In this study, our main focus is on the distribution characteristics of the rotation signal on the full disc of the solar chromosphere and its variation with the solar cycle. We found that the chromospheric rotation signal is more pronounced in the latitudinal belt of sunspot activity and tends to extend to higher latitudes, and the trend is essentially the same for each solar cycle. The chromospheric rotation signal is also found to have phase differences in latitudes. The period of the chromospheric rotation signal varies regularly in latitudes, but its phase variation is irregular. In addition, we found that the intensity background is lowest in the latitudinal belt of sunspot drift where the chromospheric rotation signal is generated, but it increases with latitude and tends to extend to higher latitudes. We discussed the possible mechanisms of the above analysis results and thought that the chromospheric rotation signal is mainly caused by sunspots and plages.
HD 60435: the star that stopped pulsating
Authors: Kurtz Donald W , Handler Gerald , Holdsworth Daniel L , Cunha Margarida S , Saio Hideyuki , Medupe Thebe , Murphy Simon J , Krüger Joachim , Brunsden E , Antoci Victoria , Hey Daniel R , Shitrit Noi , Matthews Jaymie M 
Published: December 2024

ABSTRACT
HD 60435 is a well known rapidly oscillating (roAp) Ap star with a series of alternating even and odd degree modes, making it a prime asteroseismic target. It is also an oblique pulsator with rotational inclination, i, and magnetic/pulsation obliquity, $\beta$, such that both magnetic/pulsation poles are viewed over the rotation period, $P_{\rm rot} = 7.679696$ d, determined from rotational light variations. While some roAp stars have stable pulsation mode amplitudes over decades, HD 60435 is known to have amplitude variations on time-scales as short as 1 d. We show from 5 yr of TESS observations that there is strong amplitude modulation on this short time-scale with possible mode interactions. Most remarkably, HD 60435 stopped pulsating during the time span of the TESS observations. This is the first time that any pulsating star has been observed to cease pulsating entirely. That has implications for mode interaction, excitation and damping, and is relevant to the problem of why only some stars in many pulsation instability strips pulsate, while others do not. During a 24.45-d time span of the TESS data when there was mode stability for a dipole mode and a quadrupole mode, the oblique pulsator model constrained i and $\beta$, which we used to model those modes with a magnetic pulsation model from which we determined a polar field strength of 4 kG, in good agreement with a known magnetic measurement. We modelled the frequency separations showing that they can constrain the global metallicity, something that is not possible from spectroscopy of the highly peculiar Ap atmosphere.
Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2/3 randomised controlled clinical trials
Authors: Tanaka Yoshiya , Yamanaka Hisashi , Toyoizumi Shigeyuki , Hirose Tomohiro , Takeuchi Tsutomu 
Published: December 2024

ABSTRACT

Objectives
We characterised early changes in laboratory parameters in Japanese patients with rheumatoid arthritis and assessed whether these changes at Month (M)1 were predictive of tofacitinib efficacy at M3.

Methods
This post hoc analysis included pooled data from Japanese patients receiving tofacitinib or placebo in three Phase 2/Phase 3 studies (NCT00603512; NCT00687193; NCT00847613). Outcomes included changes from baseline in laboratory parameters (Week 2 and M1/3); efficacy end points were Disease Activity Score in 28 joints, based on C-reactive protein; Disease Activity Score in 28 joints, based on erythrocyte sedimentation rate; and American College of Rheumatology-N index at M3. Univariate/multivariable analyses assessed whether changes at M1 were predictive of efficacy at M3.

Results
Overall, 467 patients receiving tofacitinib and 104 receiving placebo were included. Tofacitinib treatment was associated with decreases from baseline in C-reactive protein, erythrocyte sedimentation rate, neutrophils, and platelets and increases in lymphocytes, haemoglobin, and lipids up to M3. Decreased platelet count and increased low-density lipoprotein cholesterol and haemoglobin at M1 were predictive of changes in efficacy outcomes at M3.

Conclusions
Changes in laboratory parameters at M1 could potentially be used to assess whether tofacitinib therapy will be effective at M3; however, further investigation is needed.
FTLD-MAPT mutations and short 5′UTR Tau mRNAs increase Tau translation
Authors: da Costa Paulo J , Perret Antoine , Buée Luc , Hamdane Malika , Martin Franck 
Published: December 2024

Abstract
Tau protein plays a central role in Alzheimer’s disease (AD) and other tauopathies. Tau proteins aggregate in degenerating neurons and their expression level is critical for disease development and progression. In addition, the generation of truncated Tau species is involved in the pathological process. In the human brain, several N-terminally truncated Tau species (including Met11- and Met127-Tau) have been detected. However, both the mechanisms of their synthesis and their relevance for the diseases remain largely unclear. Several Tau messenger RNA (mRNA) isoforms with distinct 5′ untranslated regions (5′UTRs) were found in brains with tauopathies. In addition, single substitutions in the N-terminal coding sequence of Tau, namely R5H, R5L and R5C, have been associated with AD, progressive supranuclear palsy and Parkinson’s disease, respectively. Here, we investigated how the 5′ end of Tau mRNAs and the N-terminal mutations affect Tau protein synthesis. We show that both the length of the 5′UTR of Tau mRNAs and the N-terminal coding sequence largely modulate the expression level of Tau. Truncated Tau protein species are generated by an alternative translation initiation event. Thereafter, we show that the disease-associated mutations at codon #5 also increase the expression, mostly due to secondary structure modifications of the corresponding mRNAs.
The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma
Authors: McCord Matthew , Sears Thomas , Wang Wenxia , Chaliparambil Rahul , An Shejuan , Sarkaria Jann , James C David , Ruggeri Bruce , Gueble Susan , Bindra Ranjit , Horbinski Craig 
Published: December 2024

Abstract

Background
Acquired resistance to temozolomide (TMZ) chemotherapy due to DNA mismatch repair (MMR) enzyme deficiency is a barrier to improving outcomes for IDH wild-type glioblastoma (GBM) patients. KL-50 is a new imidazotetrazine-based therapeutic designed to induce DNA interstrand cross links, and subsequent double-stranded breaks, in an MMR-independent manner in cells with O-6-Methylguanine-DNA Methyltransferase (MGMT) deficiency. Previous research showed its efficacy against LN229 glioma cells with MMR and MGMT knockdown. Its activity against patient-derived GBM that model post-TMZ recurrent tumors is unclear.

Methods
We created MMR-deficient GBM patient-derived xenografts through exposure to TMZ, followed by treatment with additional TMZ or KL-50. We also generated isogenic, MSH6 knockout patient-derived GBM and tested them for sensitivity to TMZ and KL-50.

Results
KL-50 extended the median survival of mice intracranially engrafted with either patient-derived TMZ-naïve GBM6 or TMZ-naïve GBM12 by 1.75-fold and 2.15-fold, respectively (p&lt;0.0001). A low dose (4 Gy) of fractionated RT further extended the survival of KL-50 treated GBM12 mice (median survival=80 days for RT+ KL-50 vs. 71 days KL-50 alone, P=0.018). KL-50 also extended the median survival of mice engrafted with post-TMZ, MMR-deficient GBM6R-m185 (140 days for KL-50 vs. 37 days for vehicle, p&lt;0.0001). MSH6-KO increased TMZ IC50 for GBM6 and GBM12 cultures by &gt;5-fold and &gt;12-fold for cell death and live cell count outputs, respectively. In contrast, MSH6-KO actually decreased KL-50 IC50 by 10-80%.

Conclusion
KL-50-based compounds are a promising new strategy for the treatment of MGMT-deficient, MMR-deficient GBM that recurs after frontline TMZ.